{"id":1283,"date":"2023-12-23T06:25:43","date_gmt":"2023-12-23T06:25:43","guid":{"rendered":"https:\/\/o-force.info\/?p=1283"},"modified":"2025-02-02T11:02:25","modified_gmt":"2025-02-02T11:02:25","slug":"researech4","status":"publish","type":"post","link":"https:\/\/o-force.info\/index.php\/en\/2023\/12\/23\/researech4\/","title":{"rendered":"9\/25, 2023 Recanemab has been approved by the MHLW for the treatment of Alzheimer's disease; will O-Force's short peptide (JAL-TA9) in development be a safer and cheaper fundamental treatment beyond recanemab?"},"content":{"rendered":"\n<p class=\"has-large-font-size\">The short peptide we are developing (JAL-TA9) is expected to be used as a safe and inexpensive fundamental treatment for AD beyond lecanemab, as shown in the table below.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"576\" src=\"https:\/\/o-force.info\/wp-content\/uploads\/2023\/12\/Lecanemab-4-1024x576.jpg\" alt=\"\" class=\"wp-image-1352\" srcset=\"https:\/\/o-force.info\/wp-content\/uploads\/2023\/12\/Lecanemab-4-1024x576.jpg 1024w, https:\/\/o-force.info\/wp-content\/uploads\/2023\/12\/Lecanemab-4-300x169.jpg 300w, https:\/\/o-force.info\/wp-content\/uploads\/2023\/12\/Lecanemab-4-768x432.jpg 768w, https:\/\/o-force.info\/wp-content\/uploads\/2023\/12\/Lecanemab-4-320x180.jpg 320w, https:\/\/o-force.info\/wp-content\/uploads\/2023\/12\/Lecanemab-4.jpg 1280w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>The short peptide we are developing (JAL-TA9) is expected to be used as a safe and inexpensive fundamental tre [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"vkexunit_cta_each_option":"","footnotes":""},"categories":[36],"tags":[],"class_list":["post-1283","post","type-post","status-publish","format-standard","hentry","category-alzheimer"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/posts\/1283","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/comments?post=1283"}],"version-history":[{"count":20,"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/posts\/1283\/revisions"}],"predecessor-version":[{"id":2027,"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/posts\/1283\/revisions\/2027"}],"wp:attachment":[{"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/media?parent=1283"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/categories?post=1283"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/tags?post=1283"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}